Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a ...

The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

The study is a promising breakthrough that could eventually prove key to understanding the disease’s mysterious origins, its ...

The ALS therapy candidate AP-101 significantly extended patient survival and delayed the need for respiratory support in a ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

Michele Stellato, 37, and Mira Hudson, 29, are part of a largely unseen group: young women with neurodegenerative disease ALS. They joined and eventually became leaders of Her ALS Story, a support and ...

The new project combines clinical data with advanced analytics and artificial intelligence in an effort to create ...

Brooke Eby, a writer, speaker, and social media creator who lives with ALS, has been named ALS Network's Advocate of the Year. Through her advocacy work, Eby has increased awareness and raised more ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

Earlier bedtime and wake time and regular physical activity are associated with a significant reduction in ALS risk, a new ...

Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...